GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (LSE:NSCI) » Definitions » Change In Payables And Accrued Expense

NetScientific (LSE:NSCI) Change In Payables And Accrued Expense : £0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is NetScientific Change In Payables And Accrued Expense?

NetScientific's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2023 was £0.00 Mil. It means NetScientific's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Jun. 2023 .

NetScientific's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2022 was £0.00 Mil. It means NetScientific's Accounts Payable & Accrued Expense stayed the same from Dec. 2021 to Dec. 2022 .


NetScientific Change In Payables And Accrued Expense Historical Data

The historical data trend for NetScientific's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific Change In Payables And Accrued Expense Chart

NetScientific Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NetScientific Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NetScientific Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NetScientific Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of NetScientific's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NetScientific (LSE:NSCI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (LSE:NSCI) » Definitions » Change In Payables And Accrued Expense
Traded in Other Exchanges
N/A
Address
20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG
NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (LSE:NSCI) Headlines

No Headlines